The value of monoclonal antibody B72.3 for the diagnosis of breast carcinoma: experience with the first commercially available source.

@article{Prey1991TheVO,
  title={The value of monoclonal antibody B72.3 for the diagnosis of breast carcinoma: experience with the first commercially available source.},
  author={Marianne U. Prey and Carlos C W M Bedrossian and Shahla Masood},
  journal={Human pathology},
  year={1991},
  volume={22 6},
  pages={598-602}
}
One hundred cases of invasive breast carcinoma were studied using the commercially available monoclonal antibody Anti-Human Tumor-Associated Glycoprotein-72 (MAb B72.3, Biomedical Technologies Inc, Stoughton, MA) prediluted at 8.5 micrograms/mL. Forty-three cases displayed positive reactivity with this antibody. Intensity and distribution of positive staining varied among the tumor cells. Twenty-two cases had 1% or less reactive cells, while eight cases contained 40% or more positive tumor… CONTINUE READING